You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-DA-25-048: Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)

    Release Date: 09-28-2023Open Date: 02-13-2024 Due Dates: Multiple Close Date: 03-14-2026

    Purpose The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBC) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. Background In 2021, the Substance Abuse and Mental Health Services Administration (SAMHSA) noted that 61 milli ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-DA-25-047: Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)

    Release Date: 09-28-2023Open Date: 02-13-2024 Due Dates: Multiple Close Date: 03-14-2026

    Purpose The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBCs) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. Background In 2021, the Substance Abuse and Mental Health Services Administration (SAMHSA) noted that 61 mill ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PAR-24-096: Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 01-22-2024Open Date: 02-22-2024 Due Dates: Multiple Close Date: 06-23-2026

    A biomarker is a defined characteristic that is measured as an indicator of a normal biological process, pathogenic process, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints. Because the measurement of the biomarker is integral to defining the biomarke ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PAR-24-098: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 01-22-2024Open Date: 02-22-2024 Due Dates: Multiple Close Date: 06-26-2026

    Background A biomarker is a defined characteristic that is measured as an indicator of a normal biological process, pathogenic process, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints. Because the measurement of the biomarker is integral to defining ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-24-063: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 11-01-2023Open Date: 01-09-2024 Due Dates: Multiple Close Date: 08-19-2026

    Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. However, before a new chemical entity can be tested in a clinical setting, it must undergo a process of chemical optimization to improve potency, selectivity, and drug-like properties, followed by pre-clinical safety testing to meet the standards set by the Food and Drug Admin ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-24-044: NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)

    Release Date: 11-27-2023Open Date: 12-05-2023 Due Dates: Multiple Close Date: 09-06-2026

    NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treatment of n ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PAR-23-311: NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)

    Release Date: 11-27-2023Open Date: 12-05-2023 Due Dates: Multiple Close Date: 09-06-2026

    NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treatment of n ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-MD-24-007: Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)

    Release Date: 03-08-2024Open Date: 05-10-2024 Due Dates: Multiple Close Date: 12-10-2026

    Background Despite continued improvement in the health of the U.S. population with the introduction of medical and scientific advances, there continues to be an alarming disproportionate burden of illness among certain population groups. The mission of the NIMHD is to lead scientific research aimed at the development of innovative diagnostics, treatments, and prevention strategies to improve mino ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. RFA-MD-24-006: Innovations for Healthy Living- Improving Minority Health and Eliminating Health Disparities (R43/R44- Clinical Trial Optional)

    Release Date: 03-08-2024Open Date: 05-10-2024 Due Dates: Multiple Close Date: 12-10-2026

    Background Despite continued improvement in the health of the U.S. population with the introduction of medical and scientific advances, there continues to be an alarming disproportionate burden of illness among certain population groups. The mission of the NIMHD is to lead scientific research aimed at the development of innovative diagnostics, treatments, and prevention strategies to improve mino ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-24-157: Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)

    Release Date: 02-29-2024Open Date: 03-05-2024 Due Dates: Multiple Close Date: 01-06-2027

    Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), works to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Translation is the process of turning observations in the ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government